User login
Key clinical point: Little is known about what factors predict the progression of cognitive impairment (CI) and progression after a diagnosis of multiple sclerosis (MS).
Major finding: Twenty-two percent of patients had CI at baseline in newly diagnosed MS patients. At follow-up, only 14% of patients had CI. Cognitive changes within 1 year of follow-up could not be determined by baseline characteristics or initiation of treatment.
Study details: Demographic, clinical, and conventional MRI markers at baseline were investigated for CI and changes in 1,123 patients from a multicenter cohort study.
Disclosures: “The German National MS cohort and KKNMS are supported by grants from the German Federal Ministry for Education and Research.” Several study investigators reported received financial support and grants from pharmaceutical agencies.
Citation: Johnen A, et al. J Neurol. 2019 Feb;266(2):386-397. doi: 10.1007/s00415-018-9142-y.
Key clinical point: Little is known about what factors predict the progression of cognitive impairment (CI) and progression after a diagnosis of multiple sclerosis (MS).
Major finding: Twenty-two percent of patients had CI at baseline in newly diagnosed MS patients. At follow-up, only 14% of patients had CI. Cognitive changes within 1 year of follow-up could not be determined by baseline characteristics or initiation of treatment.
Study details: Demographic, clinical, and conventional MRI markers at baseline were investigated for CI and changes in 1,123 patients from a multicenter cohort study.
Disclosures: “The German National MS cohort and KKNMS are supported by grants from the German Federal Ministry for Education and Research.” Several study investigators reported received financial support and grants from pharmaceutical agencies.
Citation: Johnen A, et al. J Neurol. 2019 Feb;266(2):386-397. doi: 10.1007/s00415-018-9142-y.
Key clinical point: Little is known about what factors predict the progression of cognitive impairment (CI) and progression after a diagnosis of multiple sclerosis (MS).
Major finding: Twenty-two percent of patients had CI at baseline in newly diagnosed MS patients. At follow-up, only 14% of patients had CI. Cognitive changes within 1 year of follow-up could not be determined by baseline characteristics or initiation of treatment.
Study details: Demographic, clinical, and conventional MRI markers at baseline were investigated for CI and changes in 1,123 patients from a multicenter cohort study.
Disclosures: “The German National MS cohort and KKNMS are supported by grants from the German Federal Ministry for Education and Research.” Several study investigators reported received financial support and grants from pharmaceutical agencies.
Citation: Johnen A, et al. J Neurol. 2019 Feb;266(2):386-397. doi: 10.1007/s00415-018-9142-y.